Remote Director - Portfolio Company Strategy

Summary

Join us to free the founders and help define the value inflection path for our portfolio companies from idea to clinical proof of concept, integrating scientific, clinical, and commercial elements required to develop the next blockbuster drug.

Requirements

• MD required MD/MBA or MD/PhD preferred
• Strong scientific background with an understanding of drug discovery and development
• Clinical or business or early drug discovery exposure in an early-stage company or VC is highly desirable
• You have a high degree of scientific curiosity and enjoy thinking about the interaction between science and business
• Exceptional conceptual thinking and analytical problem-solving skills, with the ability to think strategically and identify creative solutions to complex challenges with no historical precedence
• A proven mindset of proactive continuous improvement; efficient independent worker with the ability to focus and drive for results
• You have a 'get it done' attitude and want to build something that lasts. Not only do you have the ability and the desire to architect the high-level strategy, you want to operationalize it and can dive deep into the details
• Successful in dynamic environments, and working with cross-functional multidisciplinary teams
• Highly organized and detail-oriented, with the ability to manage multiple projects and priorities simultaneously
• Excellent communication and presentation skills

Responsibilities

• Help our core scientific team and company founders map out the most efficient path to develop the next blockbuster drug
• Deeply understand the drug embodiment approach being pursued by the company and understand ‘the why’ behind prior attempts and how those paths could be improved upon by reasoning from first principles
• Work alongside the biologists and medicinal chemists to understand the potentials, constraints, and implications of the target/drug embodiment being considered
• Map out the clinical and commercial landscape by meeting with KOLs, reviewing pipeline activity/company presentations on clinical readouts, the latest scientific literature, sell-side analyst reports, databases (e.g. Global Data), etc
• Define regulatory/clinical path by incorporating recent FDA reviews and clinical trial designs (inclusion/exclusion criteria, endpoint selection)
• Integrate and synthesize all the information into potential future treatment paradigms